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The  cellular  origin  of chronic  lymphocytic leukemia  of B  cell  type  (B-CLL)  is 
unresolved  (1).  Most  cases  of B-CLL  express  detectable  surface  immunoglobulin 
(SmIg)  (albeit  weakly),  HLA-DR,  and  B  cell-associated  membrane  molecules  as 
identified by monoclonal antibodies (MAb)  (2-7). T  lymphocyte-associated antigens 
are also observed on  these  malignant  B  cells when  analyzed  by both  heterologous 
antisera (8) and MAb (9-13). In these studies no obvious normal counterparts of the 
malignant  B-CLL cells have been found in the human bone marrow (BM),  blood, 
and lymph nodes (LN) (9-11), which either suggests a surprisingly regular disturbance 
of gene expression in  B-CLL or indicates that the "normal equivalent" cells in this 
disease are rare. 
In this study we have used  the  fact that  both  B-CLL and a  subset  of normal  B 
lymphocytes form rosettes with mouse erythrocytes (MRBC) (14,  15) and can therefore 
be separated on Ficoll-Hypaque gradient from other, nonrosetting cells. The analysis 
of MRBC + B cells shows that a small population of normal B cells (2-5%) in human 
lymph  nodes  (but  virtually  none  in the  BM  and  blood)  expresses  the  phenotypic 
characteristics of B-CLL. On the basis of sensitive double-staining methods used in 
tissue sections, we suggest that at least a proportion of these normal B cells are situated 
within the germinal centers. 
Materials and Methods 
Conventional Antisera.  Goat (G) antisera to human Ig isotypes ~, 8, r, ~ and mixed/z +  6 + 
r  +  ~)  were labeled with tetraethyl-rhodamine isothiocyanate (TRITC) and used in direct 
immunofluorescenee (IF)  test.  Chicken  (C)  antiserum to HLA-DR (Ia-like)  antigens was a 
specific reagent used in indirect IF test labeled with sheep-anti-C-Ig-TRITC (16). 
MAb.  OKT1 (12) and OKT3 (17) were from Ortho Pharmaceutical, Raritan, N. J. Leu-1 
(11, 13, 18) was from Becton, Dickinson & Co., Orangeburg, N. Y. (BD 5300). Additional MAb 
were prepared at the Royal Free Hospital, London (19). RFA-1  (selected from a fusion using 
spleen  cells  of mice  immunized  with  B-CLL)  reacted  with  B-CLL,  T  lymphoeytes, and 
thymocytes in a pattern identical to OKT 1 and Leu-1. These three MAb recognize epitopes on 
the same (family of) membrane molecules  (65,000-67,000  mol wt)  (17, 19); OKT1 and RFA- 
1 show  competitive inhibition  of binding.  The hybrids  RFA-2  and  -3 were obtained  from 
fusions using spleen  cells of mice immunized with the peripheral B cells from a patient with 
non-Hodgkin lymphoma in leukemic phase (19). The common feature of these  two MAb is 
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their  lack of reactivity  on  terminal  transferase  positive  lymphocyte precursors,  pre-B cells, 
SmIg  ÷, ~+, 8- lymphocytes, and plasma cells in the BM, contrasting their strong positivity with 
various B cell subsets and plasma cells in the peripheral lymphoid organs (for more details see 
19). 
MAb were labeled with G-anti-M-Ig-FITC (green) second layers and used in various double- 
labeling  combinations  with  conventional  antisera  tagged  with  TRITC  (red)  as  described 
previously  (16, 20).  SmIg staining  was  routinely  used  with  RFA-2  and  -3  antibodies.  In 
addition, MAb were coupled to arsenilic acid (RFAkl-ARS) or to biotin (OKT3-Biotin) and 
used with appropriate second layers in combinations (G-anti-ARS-TRITC, and avidin-FITC) 
(21). 
Preparations of Celt Suspensions and MRBC Rosettes.  Leukocytes from blood and  BM  were 
passed through a Ficoll-Hypaque gradient; cells from tonsils  and LN were teased with blunt 
forceps and washed three times  (16). Cells  (107/mi)  were incubated wit h antisera  (1:20-1:40 
dilution) and/or MAb (10-100 #g/ml for 10 min at 4°C), washed three times, and stained with 
second layers (1:40 dilution, 10 rain at 4°C), followed by washing and mounting on slides  (16). 
MRBC were treated with neuraminidase (0.1 U/ml, 30 min at 37°C). The leukocytes were 
not treated with the enzyme because this step may decrease specificity (22). Leukoeytes (5 X 
106/ml)  were  incubated  with  MRBC  (10a/ml)  as a  pellet  for 5  min  at  37°C,  followed by 
incubation for 30 rain at 4°C, gently resuspended, and counted as a wet preparation on slides. 
In five experiments cells were transferred onto Ficoll-Hypaque after MRBC rosetting and spun 
(400g for 25 min). Cells in the pellet (>70% MRBC  +) were treated with 0.1% Tris-NH4CI (15 
min,  20°C)  to lyse  RBC, and  passed  through fetal  calf serum  to obtain  enriched  MRBC  + 
leukocytes  (23).  In  parallel  experiments  the  suspensions  have  been  stained  for membrane 
antigen and incubated with MRBC as described above. Preparations were studied on a Zeiss 
microscope using IV/Z attachment and phase contrast (Carl Zeiss Inc., London). 
Study of Tissue Sections.  Sections (5 jam) of frozen tonsil  (five samples)  and mesenteric LN 
(two samples from patients with no malignancy) were cut on a cryostat and dried for 10 min 
at 20°C. This was followed by fixation in equal mixtures of acetone and chloroform, lyophili- 
zation, and rehydration in buffered saline  (24). Combinations of MAb (1-5 #g/10/~1 saline, 
each)  were studied with  fluorescent second layers (1:40 dilutions;  see above) using both the 
TRITC and FITC channels. 
Results 
Phenotypes of MRBC-Rosetting  Normal B  Cells.  In the  five samples  of blood, 6.8  + 
1.4%  (SD)  of all lymphocytes were MRBC +. In tonsil  and LN, 2.3 ±  0.4%  MRBC + 
cells  were  seen.  No  MRBC +  could  be  identified  in  the  normal  BM;  only  a  few 
leukocyte clumps  ("pseudorosettes")  were formed. The percentages of SmIg  + B cells 
were  higher  (12  ±  5%  in  blood,  42  ±  11%  in  LN,  and  7  +_  3%  in  BM)  than  the 
proportions of MRBC + cells. 
The direct  observation  of membrane  staining  in MRBC  rosettes  and  the  investi- 
gation of MRBC-enriched  populations  (70-75%  purity)  yielded  similar  conclusions 
(Table I). MRBC + cells observed in both peripheral blood and LN were OKT3-  and 
stained for both SmIg and HLA-DR antigens. The staining for SmIg appeared to be 
weaker than  that  of additional  MRBC-  B  cells also present  in the suspension.  The 
MRBC + cells were strongly positive with  both  RFA-2 and  RFA-3, confirming that 
they were different from the/~+, 8- B cell population in the BM  (which are RFA-2-, 
-3-; Table I). A  further finding was that MRBC ÷ ceils in the tonsil and LN, but not 
in  the  blood,  reacted  with  all  three  MAb  recognizing  the  OKTl-type  antigen 
(OKTI+,Leu-I+,RFA-I+;  see  Fig.  1).  Thus  the  dominant  phenotype  of  normal 
MRBC ÷ cells in lymphoid organs is SmIg  + (weak), HLA-DR+,OKT3-,RFA-2+,RFA  - 
3÷,OKT 1  ÷ (Leu-I+,RFA  - 1÷). This phenotype is identical to the features of typical B- 
CLL  cases  but  different  from  the  features  of  prolymphocytic  leukemia  (PLL; 
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TABLE  I 
Subset Characterization of Normal and Malignant B cells* 
625 
BM¢ 
Normal cells 
LN and tonsil  Peripheral blood 
Malignant cells 
Peripheral blood 
All B  All B 
cells~  MRBC+§  cells:~  MRBC+§  CLL (n z  11)  PLL (n ~  5) 
SmIg  (100)  (100)  70 (weak) H  (100)  70 (weak)  70 (weak)  >90 (strong) 
MRBC  <1  5-6  >75  50  >80  >70  <2 
HLA-DR  >90  >90  >75§  >90  >75  >90  >90 
OKT3  <5  <1  <10  <2  <10  <5  <5 
RFA-2  <10 (.a  +, 8-)  >90  >75§  >90  >75  >90  >90 
RFA-3  <10 Ox  +, 8-)  >90  >75§  >90  >75  >90  >90 
OKTI**  <5  5:~:~  61§  <2  <5:~:~  >80  <5 
RFA- 1  *  *  <5  6  :~-~-  59§  <2  <5:~:~  >80  <5 
Leu-l**  <5  5  60§  <2  <5  >80  <5 
* The B cells were recognized by Smlg staining. MRBC + were studied after separation or in double marker studies. 
:~ Smlg  + cells represent 7% of BM cells, 42% of LN and tonsil,  and 12% of blood mononuclear cells. BM cells do not form 
MRBC rosettes,  and only very few MRBC-, SmIg  +, OKTI  + cells can be seen (0.3% of Smlg  + cells). 
§ MRBC  + were separated with 70-75%  purity. The corresponding values in double marker test cells were higher (80- 
90%). 
II 80% of these cells were double SmIg  +, OKTI  +. These represent a mixture of x  + and X  + B cells. 
** These three MAb recognize the same molecule (65-67,000  tool wt) (18). 
Double marker experiments with OKT  1 (or RFA- 1) and SmIg revealed that 5-6% of LN and tonsil  B cells were double 
labeled with both reagents (Fig. 2). These cells were OKT3-. The OKT1  +, SmIg  + cells were not seen in the blood, even 
when the MRBC  + population was studied. 
FIG.  1.  MRBC  rosetting cells in the human tonsil express OKT1  (a)  (phase b). 
Combination  Staining for  OKT1,  SmIg,  and  OKT3.  The  observations  above  have 
suggested that  in  tonsils MRBC + (2-2.5% of all cells)  carry both OKT1  and  SmIg. 
This finding was directly confirmed by the staining combination (6% OKTI+,SmIg  + 
doubles in Table I; Fig. 2). These doubles expressed both antigens weakly. A  similar 
proportion  of OKT1 +  cells  failed  to  express  OKT3  when  analyzed  with  hapten- 
conjugated MAb in suspension (3.5% OKTI+,OKT3  -  tonsil cells). 
Localization  of OKT1 +,  OKT3-  Cells.  MAb to MRBC  receptors are not yet avail- 
able.  For  this  reason,  the  equivalent  OKTI+,OKT3  -  cells  were  studied  in  tissue 
sections. These cells have been observed in  the germinal centers  (GC)  of tonsil and 
LN  amidst  the  rich  deposition  of antigen-antibody  complexes.  The  OKT3-  cells 
represented only  10-15% of all OKT1 + cells present  (Fig.  3). These observations do 
not  exclude the possibility that  additional  OKTI+,OKT3  -  non-T cells may also be 
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Fro.  2.  A small proportion (5-6%) of lymphocytes (---~)  in the human tonsil simultaneously and 
weakly express OKTI  (a)  and  SmIg (b)  (phase c). These cells are selectively enriched when the 
MRBC  + population is isolated  (Table I). Note that T  cells show strong OKT1  staining (SmIg-; 
[*]) and the dominant B cell population shows Smlg staining (OKT3-; [--*]). 
FIG.  3.  Sections of human tonsil were stained with RFA-I (OKTl-like) antibody (TRITC; a) and 
OKT3-biotinated antibody (FITC;  b). A  few RFA-I + cells (10%  of all  RFA-1 + cells)  are OKT3 
negative in the germinal center area shown (---*). 
Discussion 
This study identifies a  small population of B  lymphocytes that  appear to be the 
normal equivalent ceils of B-CLL. These express SmIg weakly, are HLA-DR positive, 
form MRBC rosettes, and react with MAb recognizing OKTl-like (P65) antigen(s). 
This small  subset  is unlikely to be a  (pre-)malignant  population  for three reasons. 
First, it was seen in all tonsil and lymph node samples studied. Second, MRBC + cells 
consisted of a normal mixture of t¢  + and )~+ lymphocytes. Finally, a similar subpopu- 
lation of Thy- 1-,Lyt-  1  + (homolog of Leu- 1 in mouse) non-T cells have been identified 
in the GC of murine LN (24). Thus this population is not unique for man. 
Two pieces of evidence support the possibility that the normal equivalent cells of 
B-CLL are peripheral B cells.  First, only tonsils and LN contain cells expressing both 
MRBC  and OKT1  markers together with the other B characteristics (SmIg+,HLA  - 
DR+), whereas in the BM  these MRBC +, OKT1 +,  SmIg  + cells are absent.  Second, 
two  recently standardized  MAb,  RFA-2  and  -3,  strongly  react  with  virtually  all 
peripheral B cells including B-CLL. These reagents are nevertheless unreactive with 
#+, 8- BM cells. 
It has been puzzling that cases of pre-B acute lymphoblastic leukemia as well as the 
corresponding pre-B  ceils in  normal  BM  synthesize heavy  (g)  chain  only  (25,  26), 
whereas B-CLL and the normal equivalent cells (putative early B cell precursors? See CALIGARIS-CAPPIO ET AL.  BRIEF DEFINITIVE REPORT  627 
27) synthesize excess light chains. The most likely simple explanation is that these two 
types of putative early B cell precursors represent two distinctly different stages of B 
lymphocyte development (in the BM and GC, respectively). The normal equivalent 
cells of B-CLL, putative early memory ceils (I), are now available for cell separation 
(using MRBC rosetting) and for further functional analysis. 
Summary 
An infrequent (2-3%) B lymphocyte subpopulation was found in the normal human 
tonsil  and  lymph  nodes  that  shows  the  phenotypic  characteristics  of  B-chronic 
lymphocytic  leukemia  (B-CLL)  (rosette  formation  with  mouse  erythrocytes,  weak 
expression of membrane Ig, staining for HLA-DR, and OKT1 or Leu-1  detecting a 
T  cell-associated p65 antigen).  Preliminary evidence suggests that at least a  subpop- 
ulation of these ceils is found, in small proportions, within the germinal centers. These 
cells  were  not  observed  in  the  human  bone  marrow.  B-CLL  may  involve  this 
peripheral B lymphocyte subset. 
We thank Dr. G. Goldstein for providing the OKT1  monoelonal antibody and MS.  Sylvia 
Granger for hapten-coupling of antisera. 
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